Psoriasis
Explore original articles, case reports, and podcasts that focus on psoriasis.
Eruptive Lentiginosis Within Resolved Psoriasis Plaques: A Case Report and Systematic Review of the Literature
April 2026 | Volume 25 | Issue 4 | Original Article | 324 | Copyright © April 2026
Background: Many patients with psoriasis suffer from post-inflammatory pigmentary alteration (PIPA), which remains an unmet treatment need. Eruptive lentiginosis (EL) is a rare f...
Read MoreBrodalumab's 8-Year Journey in Plaque Psoriasis: Insights into Efficacy, Safety, and Real-World Evidence
March 2026 | Volume 25 | Issue 3 | Original Article | 211 | Copyright © March 2026
Background: Plaque psoriasis is a chronic immune-mediated disease driven by proinflammatory cytokines. Brodalumab--a recombinant, human monoclonal antibody that functions as an i...
Read MoreChatGPT and DeepSeek in Dermatologic Practice: Do Artificial Intelligence Models Adhere to Psoriasis Treatment Guidelines?
February 2026 | Volume 25 | Issue 2 | Original Article | 133 | Copyright © February 2026
Background: The integration of artificial intelligence (AI), particularly large language models (LLMs), into healthcare has rapidly expanded. In dermatology, machine learning is ...
Read MoreReal-World Evidence of Brodalumab Effectiveness for the Treatment of Psoriasis
February 2026 | Volume 25 | Issue 2 | Original Article | 126 | Copyright © February 2026
Brodalumab is a recombinant, fully human monoclonal antibody antagonist of the human interleukin-17 (IL-17) receptor A. It is indicated for the treatment of moderate-to-severe plaque psoriasis in...
Read MoreMore Than Skin Clearance: Connecting Brodalumab's Mechanism of Action to Patient Outcomes in Psoriasis
December 2025 | Volume 24 | Issue 12 | Original Article | 1231 | Copyright © December 2025
Psoriasis has profound negative impacts on quality of life (QOL), including stigmatization, discrimination, occupational challenges, and mental health concerns, which are correlated with disease ...
Read MoreResolving Hyperkeratotic Psoriasis: Mechanisms of Action and Additive Effects of Fixed-Combination Halobetasol Propionate and Tazarotene
August 2025 | Volume 24 | Issue 8 | Original Article | 795 | Copyright © August 2025
Background: Hyperkeratotic plaque psoriasis represents a distinct morphological variant that is difficult to treat with topical therapies because thick lesions may impede the pen...
Read MoreOpen-Label Study: Over-the-Counter Oat Flour/Oat Oil/ Oat Extract-containing Lotion With Avenanthramides for Sensitive Skin and Psoriasis
August 2025 | Volume 24 | Issue 8 | Original Article | 782 | Copyright © August 2025
Read MoreStudy of Adjuvant Sensitive-Skin Cleansing and Moisturizing Regimen in Plaque Psoriasis
August 2025 | Volume 24 | Issue 8 | Original Article | 739 | Copyright © August 2025
Read MoreHalobetasol Propionate/Tazarotene Lotion for Scalp Psoriasis: Efficacy in Itch Reduction, Disease Clearance, and Hair Appearance
August 2025 | Volume 24 | Issue 8 | Original Article | 752 | Copyright © August 2025
Scalp involvement in plaque psoriasis is accompanied by itching and scaling that reduce quality of life and exacerbate psoriatic-associated hair loss. Challenges for the topical treatment of scal...
Read MoreComparative Efficacy of Deucravacitinib and Adalimumab for Scalp Psoriasis: An Indirect Treatment Comparison
August 2025 | Volume 24 | Issue 8 | Original Article | 788 | Copyright © August 2025
Background: Plaque psoriasis of the scalp, a common psoriasis location, remains difficult to manage. The comparative efficacy of newer oral agents, such as deucravacitinib, versus ...
Read MoreChatGPT Improves Readability of Patient Education Materials for Hidradenitis Suppurativa and Psoriasis
August 2025 | Volume 24 | Issue 8 | Features | 828 | Copyright © August 2025
Deucravacitinib With Add-On Calcipotriene/Betamethasone Dipropionate for Treating Moderate to Severe Plaque Psoriasis
August 2025 | Volume 24 | Issue 8 | Original Article | 744 | Copyright © August 2025
Background: To assess the effectiveness, safety, and quality of life in patients who received topical calcipotriene/betamethasone dipropionate (C/BD) foam added to oral deucravacitini...
Read MoreTwo-Year Treatment Persistence of Guselkumab vs Other Biologics in Plaque Psoriasis Patients
August 2025 | Volume 24 | Issue 8 | Original Article | 762 | Copyright © August 2025
Objective: The study objective was to compare long-term treatment persistence between patients initiating guselkumab vs 3 commonly prescribed biologics in the United States.Read MoreClinical Profile of Halobetasol Propionate 0.01%/ Tazarotene 0.045% Lotion in Patients With Hyperkeratotic Plaque Psoriasis
June 2025 | Volume 24 | Issue 6 | Original Article | 590 | Copyright © June 2025
Background: Hyperkeratotic psoriatic plaques, characterized by considerable elevation and scaling, present treatment challenges with topical therapy. This post hoc analysis of tw...
Read MorePDE4 Inhibitors: Bridging Molecular Insights With Clinical Impact
June 2025 | Volume 24 | Issue 6 | Original Article | 631 | Copyright © June 2025
Read MoreSpesolimab for the Treatment of Generalized Pustular Psoriasis Flares
March 2025 | Volume 24 | Issue 3 | Original Article | 242 | Copyright © March 2025
Background: Generalized pustular psoriasis (GPP) is a rare, life-threatening neutrophilic skin condition characterized by widespread sterile eruptions. Treatment approaches vary ...
Read MoreGuselkumab Efficacy by Psoriasis Disease Severity and Treatment History: VOYAGE 1 and 2 Post Hoc Analyses
February 2025 | Volume 24 | Issue 2 | Original Article | 196 | Copyright © February 2025
Background: The pivotal Phase 3 VOYAGE 1 and VOYAGE 2 studies established the robust efficacy and safety of guselkumab for up to 5 years in patients with moderate-to-severe psori...
Read MoreAn Unusual Case of Psoriasiform Dermatitis Treated With Dual Biologic Therapy and Literature Review
February 2025 | Volume 24 | Issue 2 | Case Reports | 207 | Copyright © February 2025
Previously believed to be of distinct immunopathogenesis, atopic dermatitis (AD) and psoriasis (PsO) spectrum may permit immunologic shifts to favor the opposing inflammatory states following bio...
Read MoreStructural Insights: What Makes Some IL-23 Biologics More Effective in Psoriasis
October 2024 | Volume 23 | Issue 10 | Features | 903 | Copyright © October 2024
Read MoreSelective Tyrosine Kinase 2 (TYK2) Inhibition in Plaque Psoriasis
August 2024 | Volume 23 | Issue 8 | Original Article | 645 | Copyright © August 2024
Members of the Janus kinase (JAK) superfamily, comprising tyrosine kinase 2 (TYK2) and JAK1, JAK2, and JAK3, mediate signaling by cytokines (eg, interleukin [IL]-23) involved in psoriasis pathoge...
Read More© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
